The FDA has granted Priority Review to TAR-200 for the treatment of patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors ...

Erik Menendez remains in fair condition Tuesday after he was transported to a medical facility about a month before a ...